The Health 202: Trump vowed drug companies would lower prices. That hasn’t happened yet. image

The Washington Post, October 1, 2018
Paulina Firozi, quoting Rachel Sachs (Academic Fellow Alumna)


Read the full article

From the article: 

The AP found in the two months after Trump’s prediction of major cuts,  price increases outpaced decreases by a 16.5-to-1 ratio. During that time there were 395 price increases and 24 decreases. The analysis, based on 26,176 list price changes in the United States for brand-name prescription drugs from January through July in the years 2015 through 2018 , also found that there were 96 price increases for every price decrease. But overall, there were also fewer price hikes than in comparable periods in previous years, according to the report.

Simply put: The data signals the administration’s approach hasn’t had an immediate impact on prescription prices.

“I don’t need to look at the analysis to know that, but the analysis supports that,” said Rachel Sachs, an associate professor of law at Washington University School of Law in St. Louis. She said the administration’s drug pricing blueprint announced in May was “more of a set of thoughts on how to address the problem than an actual action plan.”

Read more here!

biotechnology rachel sachs